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Differential expression of the inflammation
marker IL12p40 in the at-risk mental state
for psychosis: a predictor of transition to
psychotic disorder?
Melanie Föcking1, Patrick Dicker2, Lorna M. Lopez1, Mary Cannon1,5, Miriam R. Schäfer3, Patrick D. McGorry3,
Stefan Smesny4, David R. Cotter1,5*† and G. Paul Amminger3†
Abstract
Background: The identification of biomarkers of transition from the at-risk mental state (ARMS) to psychotic
disorder is important because early treatment of psychosis is associated with improved outcome. Increasing
evidence points to an inflammatory contribution to psychosis.
We questioned whether raised levels of plasma inflammatory markers predict transition from ARMS to psychotic
disorder and whether any such predictors could be reduced by omega-3 (ω-3) polyunsaturated fatty acids (PUFAs).
Methods: We measured the levels of 40 neuroinflammation biomarkers using a commercially available immunoassay
kit. Firstly, we compared inflammatory markers in subjects in the ARMS who transitioned to psychotic disorder (n = 11)
compared to subjects who did not (n = 28). Then we compared inflammatory markers in all subjects before and after
ω-3 PUFA treatment (n = 40).
Results: Our data provides preliminary evidence that elevations in the baseline plasma levels of the inflammatory
marker IL12/IL23p40 are associated with transition from ARMS to psychotic disorder. IL12/IL23p40 levels did not
change following 12 weeks administration of ω-3 PUFAs. These findings provide evidence that elevated plasma
IL12/IL23p40 is a potential biomarker of increased risk for transition to psychotic disorder.
Conclusion: Further studies are required to confirm and extend this finding. Our results do not provide support for the
possibility that administration of ω-3 PUFAs act to reduced transition to psychotic disorder by reducing blood levels of
IL12/IL23p40.
Trial registration: ClinicalTrials.gov, a service of the U.S. National Institutes of Health, Identifier: NCT00396643, last
updated December 20, 2007. Retrospectively registered.
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Background
Over the past few years there has been a substantial inter-
est in the role of inflammation in “priming” the brain for
psychosis based on epidemiological, post-mortem, genetic
and therapeutic data [1, 2]. Elevated levels of cytokines
and other markers of inflammation have been reported in
schizophrenia and mood disorder [3–6].
Epidemiological studies have shown that elevations in
maternal C-reactive protein (CRP) and pro-inflammatory
markers, such as cytokines IL-8 and TNFα, in addition to
elevations in IL6 in childhood, predict psychotic disorder
[1, 7, 8]. It has been proposed that exposure to an elevated
inflammatory state in prenatal life or early childhood, pos-
sibly in association with a genetic vulnerability towards
dysregulation of the immune system, “primes” [9] the
brain and leads to vulnerability state which may be
expressed clinically as early psychotic symptoms [10].
Further stressors during development such as adolescent
bullying, trauma, stressful life transitions or substance use
may serve to convert this vulnerability into disorder [11].
The primary cause of the elevated ‘inflammatory tone’ is
not known. Maternal infection is an obvious causal
candidate [12–15], but inflammation may also reflect a
stress-related loss of normal glucocorticoid-associated
anti-inflammatory tone [16] and represent a common
pathway mediating a diverse range of pregnancy-related
and early childhood exposures associated with psychotic
illness [17].
Early treatment of psychosis is associated with im-
proved outcome [18]. However there is no biomarker
signature predicting those at increased risk of developing
a psychotic disorder among those already known to be
at risk due to their symptom profile, the so-called ‘at-risk
mental state’ (ARMS) criteria for psychosis. Approxi-
mately 30–40 % of subjects in the ARMS convert to
psychotic disorder [19]. While inflammatory biomarkers
are clearly important in psychosis, few previous studies
have examined whether blood markers of inflammation
distinguish those who convert to psychotic disorder
from those who do not [6, 20]. The National Institute of
Mental Health has prioritised the identification of such
biomarkers as targets for the development of new ther-
apies. Among such potential therapeutic agents are
omega-3 fatty acids which have been shown to protect
subjects in the ARMS from developing acute psychotic
disorder [21].
Amminger and colleagues recently reported on the ef-
fects of long-chain omega-3 (ω-3) polyunsaturated fatty
acids (PUFAs) for indicated prevention of psychosis in
adolescents and young adults at risk of developing
psychosis according to ARMS criteria. The results of this
trial indicated that a 12-week intervention with ω-3
PUFAs significantly reduced the risk of transition to
psychosis at 1 year follow-up [21, 22]. The ω-3 PUFA
group also showed greater improvement in positive,
negative and general symptoms as well as in functioning.
It is of interest that the protective effects were sustained
for the 12-month follow-up period [22], an effect that
could be explained by the neuroprotective properties of
ω-3 PUFAs [23]. Given the importance of inflammation
in psychotic disorder we asked whether the presence of
raised markers of inflammation among ARMS subjects
could distinguish those who transition to psychotic dis-
order (ARMS-P) from those who do not (ARMS-NP).
We also asked whether ARMS subjects treated with ω-3
PUFAs showed a reduction in any of such inflammatory
plasma markers.
Methods
Plasma samples
Plasma samples collected from subjects aged 13–25
years meeting at least one of three operationally defined
criteria for increased risk for psychosis (i.e., attenuated
psychotic symptoms, brief limited intermittent psychotic
symptoms, or a genetic risk with decreased functioning)
and well-validated groups of risk for psychosis according
to [19, 24–26] were included in the study if they did not
fulfill any of the exclusion criteria. These included a pre-
vious history of a psychotic disorder or manic episode, a
substance-induced psychotic disorder, acute suicidal or
aggressive behavior, a current substance dependence ex-
cept for cannabis dependence, neurological disorder,
relevant structural brain changes, IQ of less than 70,
previous antipsychotic or mood-stabilizing treatment for
longer than 1 week, previous supplementation with ω-3
PUFAs within 8 weeks of inclusion in the trial, abnormal
laboratory values for transaminases, thyroid hormones,
C-reactive protein, bleeding parameters or any other se-
vere intercurrent illness that may have put the person at
risk. For further details please see [21, 22].
Study design
Subjects studied were included in a double-blind, placebo-
controlled randomized controlled trial with a 12-week
intervention period of 1.2 g/d ω-3 PUFAs or placebo (Trial
registration: clinical trials.gov Identifier: NCT00396643).
During the intervention period participants received
weekly assessments for 4 weeks and then at 8 and 12 weeks,
as well as at the 6- and 12-month follow-up [22]. All pa-
tients who progressed to a first episode of psychosis were
independently confirmed by non-project psychiatrists and
then treated accordingly if needed. The Structured Clinical
Interview for DSM-IV-TR Axis I Disorders was used to as-
certain psychiatric diagnoses at baseline, at 12-months
follow-up, and at 12 months and was also supplemented
by additional sources, e.g. medical records review (please
see Amminger et al. [21] for further details). Eighty-one pa-
tients agreed to participate in the trial and gave informed
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written consent. They were then assigned to one of the
two intervention arms (n = 41 ω-3 PUFA, n = 40 placebo)
[22]. From these samples the majority were available for
the current study (n = 40 ω-3 PUFA, n = 39 placebo). Be-
cause the conversion rates differed significantly between
the treatment groups in our treatment trial, and to elimin-
ate treatment effects, we only investigated those partici-
pants who received placebo in the prediction analysis. The
study was approved by the Medical University of Vienna
ethics committee, and written informed consent was ob-
tained from all participants (parental or guardian consent
was obtained for those aged under 18 years). The study
was also approved by the local ethics committee (Royal
College of Surgeons in Ireland Research Ethics Committee
(Application No. REC 766)).
Assessment of inflammation markers - Immunological
assays
Neuroinflammatory biomarkers were measured with the
V-PLEX Human Biomarker 40-Plex Kit (Mesoscale
Discovery (MSD), Maryland, US) according to the manu-
facturer’s instructions. In brief, 250 μl plasma (10–50 μl
for each of the five plates) was diluted as recommended in
buffer and 25 μl applied to the bottom of each well in du-
plicate, incubated for two hours, washed three times and a
solution containing detection antibodies was applied and
incubated for another two hours. Subsequently the plate
was washed again three times before the read buffer was
applied and the plate read in an MSD instrument. The in-
strument measures the intensity of emitted light to pro-
vide a quantitative measure of analytes in the sample.
Forty markers were quantitatively measured at the same
time. This allowed simultaneous detection of cytokines
and chemokines with high precision and accuracy. These
analytes were: bFGF, CRP, Eotaxin, Eotaxin-3, Flt-1,
GM-CSF, ICAM-1, IFN-γ, IL-1α, IL-1β, IL-10, IL-12
p70, IL-12/IL-23p40, IL-13, IL-15, IL-16, IL-17A, IL-2, IL-4,
IL-5, IL-6, IL-7, IL-8, IL-8 (high abundance), IP-10, MCP-1,
MCP-4, MDC, MIP-1α, MIP-1β, PlGF, SAA, TARC, Tie-2,
TNF-α, TNF-β, VCAM-1, VEGF, VEGF-C, VEGF-D.
Each sample was tested in duplicate and the levels re-
ported represent the mean of the duplicates. Sensitivity
and coefficient of variation measures were within their
expected ranges.
Statistical analysis
For statistical analysis, calculated concentration levels
were first checked to be within detection limits of the
assay and having a coefficient of variation of at most
20 %. The data were log transformed to remove skew-
ness or the potential influence of outliers.
In the placebo group differences between those
ARMS-P (n = 11) and ARMS-NP (n = 28) were deter-
mined using a two-sample t-test and a non-parametric
analysis (Wilcoxon rank-sum test). Potential confoun-
ders, namely body mass index, age, gender, tobacco use,
alcohol use, exposure to illicit drugs, marijuana use, anti-
depressant medications and benzodiazepine use were
compared between groups. Where significant differences
between these confounding factors were identified (see
Table 1) these were included as co-variates in a
secondary analysis.
Because of the known potential importance of smok-
ing on inflammatory cytokine markers, for any candidate
inflammatory marker showing differential expression be-
tween groups, we also compared its levels between
smokers and non smokers in ARMS-NP alone to deter-
mine the effect of smoking on that specific cytokine.
In order to test the effect of ω-3 PUFAs treatment we
performed a repeated measures analysis of cytokine
levels compared between baseline and after 12 weeks
treatment (n = 40).
SAS Version 9.2 was used for data management and
statistical analysis.
Results
We performed our experiments in baseline plasma sam-
ples from 39 individuals in the ARMS placebo and 40
subjects in the ω-3 PUFA treatment group (Table 1)
[21]. Participants were followed up for 1 year during
which time they received non-neuroleptic state-of-the-
art care unless they transitioned to psychotic disorder.
For a detailed description of therapeutic interventions
see Amminger et al. 2010 [21]. After 1 year, 11 of 39 in-
dividuals of the placebo group transitioned to psychotic
disorder and 28 individuals remained at risk (in omega-3
PUFA treated group 2/40 transitions). Fold changes for
each marker between ARMS-P and ARMS-NP groups
are listed in Fig. 1.
No group differences in body mass index, age, gender,
tobacco use, and alcohol use, exposure to illicit drugs,
marijuana use, antidepressant medications and benzodi-
azepine use were observed and therefore with the excep-
tion of BMI and smoking these co-variates were not
included in our analysis comparing the levels of inflam-
matory markers between groups (Table 2 and Fig. 1).
Of the 40 biomarkers that were assayed, 35 passed
quality control (CRP, Eotaxin, Eotaxin 3, ICAM-1, IFNγ,
IL-10, IL-12/IL23p40, IL-15, IL-16, IL-17, IL-1α, IL-1β,
IL-5, IL-6, IL-7, IL-8, IP-10, MCP-1, MCP-4, MDC,
MIP-1α, MIP-1β, PIGF, SAA, sFLT-1, TARC, Tie-2,
TNFα, TNFβ, VCAM-1, VEGF, VEGF-A, VEGF-C
VEGF-D, bFGF). One marker was found to be signifi-
cantly increased in ARMS-P compared with ARMS-NP –
Interleukin 12/23 subunit p40 (IL12/IL23p40, henceforth
called IL12/23) (1.6 fold, p = 0.0043, Fig. 2). This however
did not survive formal Bonferroni correction (required
p-value for 35 tests p < 0.0014). In addition, to account
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for potential confounding effects of smoking, ANCOVA
including Body Mass Index (BMI) and smoking as covari-
ates was undertaken as these variables are known from
the literature to have effects on inflammatory markers
(see e.g. [27, 28]). Group differences in IL12/23 changed
to (1.47 fold, p = 0.0025) and this effect was not sig-
nificantly affected by BMI or smoking. In addition, no sig-
nificant differences in IL12/23 levels were observed
between ARMS-NP smokers versus non smokers (1.23
fold, p = 0.213).
Given the evidence that IL12/23 is elevated among
ARMS-P compared to ARMS-NP and the data suggesting
clinical efficacy of ω-3 fatty acids in preventing transition
from ARMS-NP to ARMS-P [21], we hypothesized that
treatment with ω-3 PUFA will reduce levels of the inflam-
matory cytokine IL12/23. We investigated this question by
Table 1 Demographic information of study subjects. Data are expressed as mean +/- s.e.m.
Placebo Omega3
ARMS-NP ARMS-P p-value
N 28 11 40
Age Years (SD) 16.24 (0.34) 15.88 (0.33) 0.545 16.9 (0.38)
Gender (female/male) 20/8 7/4 0.635 26/14
BMI (kg/m2) 21.17 (0.61) 21.3 (1.08) 0.906 21.05 (0.66)
Smoking (yes/no) 17/11 7/4 0.866a 17/23
Alcohol use (rarely/regularly) 15/13 6/5 0.956a 23/17
Marijuana use (yes/no) 3/25 3/8 0.197a 6/34
Prescription medication
Antidepresant (yes/no) 9/19 4/7 0.801a 14/26
Benzodiazepine (yes/no) 1/27 2/9 0.123a 7/33
aIndicates where a chi-Square comparison was used to analyse the data
Fig. 1 Changes in baseline inflammatory marker levels between ARMS-NP and ARMS-P. Marker fold changes and 95 % confidence interval are shown
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comparing IL12/23 levels at baseline with 12 weeks
plasma samples in 40 ARMS subjects who were treated
with ω-3 PUFA over a 12 week period. The neuroinflam-
mation biomarker IL12/23 passed quality control and no
significant difference was observed in its levels before and
after the 12 weeks ω-3 PUFA treatment (fold change
-1.02, p = 0.82) regardless of correction for the potential
confounders.
Discussion
This study identifies the plasma inflammatory marker
IL12/23 as a potential candidate biomarker of transition
from the ARMS to psychotic disorder (ARMS-P). Our
data is consistent with previous reports implicating in-
flammatory markers in psychosis [5, 29, 30] and mood
disorders [3, 5] but is among the first to identify an in-
flammatory marker which distinguishes subjects in the
ARMS who will transition to psychotic disorder at 1 year
follow-up compared from those who will not. The find-
ing is important as it may help to identify those who will
benefit from earlier, more effective treatment [31].
IL-12p40 plays critical roles in regulating the inflamma-
tory response such as that to prenatal and early develop-
mental infections [32], and autoimmunity [33] both of
which have been implicated in schizophrenia [34]. Our ob-
servations of elevated IL12/23 relates specifically to the
p40 subunit of IL-12, which can form a heterodimer with
p19 to form IL-23, or with the p35 subunit to form IL-
12p70 [35]. In keeping with our observation of increased
Table 2 Changes in baseline inflammatory marker levels between
ARMS-NP and ARMS-P. Mean values, fold changes and p-values
are shown
Marker ARMS-NP
mean [pg/ml]
ARMS-P
mean [pg/ml]
Fold change p-value
converter
CRP 597752 340155 -1.7573 0.2979
Eotaxin 81.22 92.825 1.1429 0.2969
Eotaxin-3 13.06 10.378 -1.2584 0.0997
IFN-γ 5.0019 4.8783 -1.0253 0.9190
IL-10 0.2562 0.2717 1.0607 0.7452
IL-12p40/IL23 98.095 154.19 1.5719 0.0043
IL-15 2.1771 1.8656 -1.1669 0.0790
IL-16 169.02 162.19 -1.0421 0.8128
IL-17 2.2659 2.3853 1.0527 0.7782
IL-1α 3.3439 2.2814 -1.4657 0.5685
IL-β 0.1647 0.0962 -1.7128 0.2683
IL-5 1.5655 0.5521 -2.8355 0.2708
IL-6 0.3867 0.372 -1.0394 0.8902
IL-7 3.7935 2.8095 -1.3502 0.3314
IL-8 3.7555 3.6444 -1.0305 0.7863
IP-10 267.65 261.03 -1.0254 0.8869
MCP-1 68.28 63.834 -1.0696 0.4551
MCP-4 45.132 43.87 -1.0288 0.8587
MDC 1105.3 1147.5 1.0382 0.7187
MIP-1α 13.325 12.682 -1.0507 0.6390
MIP-1β 54.783 48.465 -1.1304 0.2071
PIGF 47.649 43.104 -1.1054 0.4018
SAA 1.24E + 06 934565 -1.3303 0.4908
TARC 100.52 77.035 -1.3048 0.3085
TNF-α 2.2792 2.3577 1.0344 0.7914
TNF-β 0.2566 0.2434 -1.0541 0.6914
Tie-2 11001 10973 -1.0025 0.9798
VEGF 86.718 70.914 -1.2229 0.3055
VEGF 31.114 23.396 -1.3299 0.2421
VEGF-C 179.68 121.52 -1.4785 0.1958
VEGF-D 851.82 775.19 -1.0988 0.3087
bFGF 25.327 20.382 -1.2426 0.5351
sFlt-1 90.022 88.16 -1.0211 0.8671
sICAM-1 215136 221081 1.0276 0.8545
sVCAM-1 427575 433463 1.0138 0.9203
Fig. 2 Box plots for IL12/23 in plasma from ARMS-NP and ARMS-P.
Each point represents the concentration of IL12/23 (pg/ml) in a
single plasma sample. Horizontal lines show median values for
each group
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IL12, upregulation of IL-17 and Th17 cells has been ob-
served in first episode drug naïve schizophrenia [36], al-
though another study of first episode drug naïve subjects
demonstrated a reduction in IL12p40 compared to
matched healthy controls [29]. In keeping with our findings
a meta-analysis of serum cytokine alterations in schizo-
phrenia or related psychotic disorder patients found in-
creased levels of interleukin, among those IL6, IL12, TNF-
α, TGF-β although with significant heterogeneity [37].
Three recent studies have investigated inflammatory
markers in ARMS subjects in addition to other markers of
oxidative stress and metabolism and hormones [4, 6, 20].
Perkins and colleagues (2015) compared plasma samples
of clinically high risk (CHR) subjects who developed
psychosis with CHR who did not, and observed a set of 15
biomarkers which distinguished ARMS and schizophrenia
subjects combined from healthy controls, and also pro-
vided preliminary evidence, that some inflammatory and
stress related proteins distinguish ARMS from schizophre-
nia [6]. Hayes and colleagues (2014) studied cerebrospinal
fluid from subjects in the ARMS and schizophrenia and
observed another different set of 15 inflammatory markers
(only IL8 overlapping with Perkins and colleagues (2015))
that distinguished ARMS and schizophrenia combined
from normal controls (n = 35) and a subset which distin-
guished ARMS subjects from schizophrenia, although
once again significant differences did not survive correc-
tion for multiple testing [4]. Stojanovic and colleagues
(2014) studied IL6 and CRP levels in ARMS, psychotic
disorder and normal controls and observed elevated IL6
in the combined ARMS and psychotic disorder groups
compared to controls, and non significant elevations
among ARMS who transitioned compared to those who
did not [20]. Together with our own data these findings
offer promise that altered levels of inflammatory cytokines
and indeed hormones and stress markers may contribute
usefully as a component of a risk prediction tool for tran-
sition from ARMS to psychotic disorder [38]. However,
further work is required to replicate and refine the risk
signature and to combine blood or CSF-based biomarkers
with the most robust neuropsychological, neuroimaging
and genomic risk predictors [39]. Of note, while Perkins
and colleagues (2015) included IL12/23 in their panel they
did not include it in group comparisons because it was
below the levels of detection in >20 % of their sample [6].
Specifically in relation to inflammatory markers it will also
be critical to characterise the changes longitudinally and
in relation to ARMS, psychotic disorder, psychiatric dis-
order generally, severity of illness, and potentially to ad-
ministered drug treatments. Furthermore, the possibility
that there are distinct inflammatory subtypes of psychosis
must be considered. A mechanistic role of IL12 in psych-
osis formation could be microglia activation [40] and post-
mortem studies suggest that there is an inflammatory
subgroup of schizophrenia with pronounced microglial ac-
tivation [41].
Having identified IL12/23 as a potential biomarker of
transition from ARMS to psychotic disorder, we tested
whether treatment of ARMS subjects with ω-3 PUFA over
a 12 weeks period reduced the levels of IL12/23 when
comparing baseline and week 12 plasma samples. No such
reduction was observed. This suggests that ω-3 PUFA do
not act through reductions in IL12/23 when mediating
their proposed antipsychotic [42] or psychosis preventing
effects [43]. Previous studies have suggested that ω-3 PUFA
may have anti-inflammatory effects which mediate their
clinical efficacy in depression [44], neurodegenerative dis-
orders [45] and psychosis [21, 46] although to our know-
ledge no previous study has assessed the effects of ω-3
PUFA augmentation on inflammatory cytokine levels in
the ARMS. While our findings provide no support for the
view that ω-3 PUFA may act by reducing candidate inflam-
matory cytokines, further work is required as ω-3 PUFA
may require longer treatment periods or different doses to
exert effects on inflammatory cytokines, or may be only ef-
fective in an inflammatory subgroup of at risk subjects.
Our study has some weaknesses that need to be consid-
ered. Firstly, the sample may be viewed as relatively small.
Our study involved 39 ARMS subjects in the placebo group
(of whom 11 transitioned to psychosis at 1 year follow-up)
and 40 in the ω-3 PUFA treatment group. While these
numbers limit the statistical power to detect small differ-
ences between groups it should be appreciated that these
are unique samples that require a great investment of re-
sources to identify and follow-up. Secondly, normal con-
trols were not available and as a result we could not
characterise whether ARMS subjects generally demonstrate
elevations in inflammatory markers compared to normal
controls as suggested by previous studies in ARMS groups
[4, 6]. Thirdly, the study used the same inclusion and exclu-
sion criteria originally proposed by the PACE Clinic in Mel-
bourne [47]. In these studies cannabis dependency was not
excluded because this would have resulted in a non-
representative Ultra-High-Risk sample, since the rates for
cannabis dependency were very high in the Ultra-High-
Risk patients. However, as in the main outcome papers
from the cohort used in this work [21, 48], the rates at
baseline were quite low for substance abuse in general as
well as for cannabis. Fourthly, our study did not assess the
broad array of markers involving oxidative stress and meta-
bolic function that have been implicated by other studies of
post-mortem brain [41, 49] and plasma in ARMS. More
work is needed to target these markers. Fifthly, the issue of
potential confounders and multiple comparisons need to
be considered. Our finding of increased IL12/23 in ARMS-
P compared to ARMS-NP while highly significant did not
survive formal correction for multiple comparisons accord-
ing to Bonferroni adjustment and thus must be viewed as
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preliminary and in need of further replication. Nonetheless
IL12/23 has been implicated previously in psychosis and
our findings support and extend these latter findings [29].
BMI and smoking can also influence plasma cytokine levels
and inclusion of these variables in our ANCOVA slightly
reduced the significance of the findings. Such a correction
may not however have been appropriate as IL12/23 did not
differ among ARMS-NP who smoked compared to those
who did not, and BMI was not different between groups.
Finally, outcome data in terms of transition to psychotic
disorder is based on 1 year follow-up and therefore our
findings are only relevant in terms of this relatively short-
term risk of transition to psychotic disorder. It is possible
that other inflammatory markers may predict longer term
outcome. As longer term outcome data becomes available
we plan to reanalyse the data to clarify if different markers
predict longer term outcome.
Conclusions
In conclusion, our data indicates that an elevation in the
plasma level of the inflammatory cytokine IL12/23 may
distinguish subjects in the ARMS who will develop a
psychotic disorder from those who will not. Future work is
needed to confirm this finding in larger cohorts and to
characterise the longitudinal pattern of changes in inflam-
matory markers over time and in relation to illness staging.
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